BridgeBio Pharma, a Phase 3 biotech developing therapies for genetic diseases, filed on Friday with the SEC to raise up to $225 million in an initial public offering.
The Palo Alto, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol BBIO. BridgeBio Pharma filed confidentially on February 14, 2019. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James are the joint bookrunners on the deal. No pricing terms were disclosed.
